As Chief Medical Officer, Rich Christie, MD, PhD, oversees the medical and scientific aspects of the AiCure portfolio. Dr. Christie brought extensive C-suite and clinical experience to AiCure when he first joined as Chief Development Officer, building on his previous experience as Global Head, Development Science and Innovation at Roche, as Vice President, External Research and Early Development at Johnson & Johnson, and CEO of Solaris Therapeutics. Rich received an SB from MIT, and an MD/PhD from Harvard, where he patented and developed novel optical methods for the study of Alzheimer’s disease.
Digital biomarkers today serve as a valuable monitoring tool, providing details about a patient’s general health and response to treatment. But, as technology continues to develop, they could fuel predictive insights about a patient’s future health outcomes and disease trajectory, as well as demonstrate measurable quality of life improvements.